Cogent Biosciences Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Cogent Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $54.25. The average 1-year stock price forecast is 31.17% higher than the current stock price, while the lowest is $35 (-15.38%) and the highest is $72 (+74.08%).

Price Target: $54.25 (+31.17%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$35	$54.25	$55	$72
Change	-15.38%	+31.17%	+32.98%	+74.08%

* Price targets were last updated on Jun 17, 2026.

Analyst Ratings

The average analyst rating for Cogent Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	9	9	9	9	9	9
Buy	2	2	2	2	2	2
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $55	Buy	Reiterates	$55	+32.98%	Jun 17, 2026
Laura Prendergast Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $45	Buy	Maintains	$45	+8.80%	Jun 15, 2026
David Nierengarten Wedbush	Wedbush	Buy Maintains $55	Buy	Maintains	$55	+32.98%	Jun 15, 2026
Anupam Rama J.P. Morgan	J.P. Morgan	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 1, 2026
Michael Yee UBS	UBS	Buy Maintains $60	Buy	Maintains	$60	+45.07%	Jun 1, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

9.90M

Revenue Next Year

348.89M

from 9.90M

3,423.11%

from 9.90M

EPS This Year

-2.26

from -2.11

EPS Next Year

-0.94

from -2.26

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	9.90M
Operating Income	-75.55M	-147.84M	-208.13M	-275.94M	-333.36M	-415.13M
Net Income	-72.27M	-140.24M	-192.41M	-255.86M	-328.94M	-391.56M
EPS	-	-	-	-	-2.11	-2.26
Free Cash Flow	-31.78M	-67.08M	-86.68M	-115.91M	-152.49M	-308.00M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	30.1M
Avg	9.9M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	7,884.5%
Avg	3,423.1%
Low	984.6%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.96
Avg	-2.26
Low	-2.70

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-